Saturday, February 2, 2008

Encysive pharmaceutical products receives warning letter to Delisting from nasdaq

_ HOUSTON, December. 19, 2007 (PRIMe newsWIRE) — Encysive product Inc. (nasdaq:ENCY) announce the fact that today it received delisting warning a letter of D nasdaq stock market, notifying it that D company closing cost per portion for its generally stock its under D $1,00 minimum offer price for 30 in the following trading day _ consequently, Encysive do not meet any longer nasdaq’s continue listing criterion and has 180 calendars day, or to June 16, 2008, to recover observance _ during this 180-day period, Encysive portion becomes to continue to act at D nasdaq.


_ _ to recover observance, D closing price by D company stock must to remain general at or over $1.00 for a minimum of 10 in the following business day before D end of D 180 calendars do not offer day observance period _ to D company be able to also be suitably for additionally 180 calendars a day observance period by transfer ring D nasdaq main market _ if D company to recover observance end of D observance period (or any extension of it) and to select too not fallen nasdaq’s decision too delist to be generally stock, Encysive’s general stock become its delisted of nasdaq.


_ _ over Encysive product


_ Encysive product Inc. its global biopharmaceutical company engage molecule in D discovery, development and commercialization of novel, synthetically, small build up to address unmet medically need _ our research and development program its predominantly focused on D treatment and prevention of interrelated illness of D container endothelium and use our expertise in D range from D intravascular inflammatory process, refer like D inflammatory cascade, and container illness _ to learn more over Encysive product please visits our web site: _ www.encysive.com.


_ _ D Encysive product Inc. trade mark its available at http://www.primenewswire.com/newsroom/prs/?pkgid=843


_ this it operate release contained “forward — look statement” within D meaning of section 27A of D security function from 1933, how change, and section 21E of D security exchanges functions from 1934, as changes _ this forward — look statement its dependent on determines danger, bends and uncertainty that cause result to actually differentiate materially of jen to project _ under jen danger, bends and uncertainty can to be: _ D probability that ours generally stock act in distance to remain acceptable register on nasdaq; _ D possibility of its suitably for additionally time to recover observance; _ D effect of any delisting of ours generally stock, as well as more specifically danger, to bend and uncertainty verge Encysive as jen specify in its report on form 8-K, 10-Q and 10-K arrange with D STATE OF security and exchange commission _ given this danger, bend and uncertainty, any or all from this forward — statement can to be examined to have wrongly _ therefore you look not be supposed not to build for possibly such forward — to look statement _ in addition, Encysive take up no task to updates or improve this forward — statement _ D look privately security law case improve function from 1995 make possible this discussion.


_ _ IN CONNECTION STEPPING: _ Encysive product investors: _ ann Tanabe, VP, investor relation and korporativ communication (713) 796-8822 BMC communication means: _ Dan Budwick (212) 477-9007 Ext.. _ 14 D Forelle group of Marcy Strickler (646) 378-2927


_. _


source
bookmark this post:

Digg Encysive pharmaceutical products receives warning letter to Delisting from nasdaq at Digg.comBookmark Encysive pharmaceutical products receives warning letter to Delisting from nasdaqBookmark  Encysive pharmaceutical products receives warning letter to Delisting from nasdaq at Spurl.netBookmark Encysive pharmaceutical products receives warning letter to Delisting from nasdaq at Simpy.comBookmark Encysive pharmaceutical products receives warning letter to Delisting from nasdaq at NewsVineBookmark Encysive pharmaceutical products receives warning letter to Delisting from nasdaq at Furl.netBookmark Encysive pharmaceutical products receives warning letter to Delisting from nasdaq at reddit.comFark Encysive pharmaceutical products receives warning letter to Delisting from nasdaq at Fark.comBookmark Encysive pharmaceutical products receives warning letter to Delisting from nasdaq at YahooMyWebBookmark Encysive pharmaceutical products receives warning letter to Delisting from nasdaq at BlinkBits